INDEX TO VOLUME 161

Author Index

Aaby, P., 171, 1088
Åberg, H., 942
Abraham, S. N., 1153
Acheson, D. W. K., 134
Ackermann, R., 1203
Agatensi, L., 1276
Agopian, M. S., 1312
Aguero, S. M., 85
Akil, B., 91
Akuffo, H., 775
Al-Qubati, Y., 1309
Alberton, B., 769
Albright, R. E., 1068
Alen, J. C., 1187
Allegra, C. J., 91
Ambrosino, D. M., 922
Amouroux, J., 585
Anderson, J. F., 811
Anderson, L. J., 603, 640
Andersson, J., 903
Andrieu, J. M., 430
Aoki, S., 755
Appel, J., 956
Arbeit, R. D., 230
Archer, D. L., 358
Arduino, M. J., 85
Armstrong, D., 296, 381, 397
Arthur, M., 230
Asano, Y., 1095
Asher, L. V. S., 7
Ashkenazi, S., 961
Ashley, R., 653
Aso, Y., 1128
Assaykeen, T., 1078
Atkins, M., 647
Auclair, P., 721
Augustine, N. H., 236
Azevedo-Bernarda, R., 156
Bøvre, K., 365
Baba, M., 208
Bacha, A., 150
Bacher, J., 755
Baddour, L. M., 1153
Baker, B. A., 1112
Baker, C. J., 65, 917
Ballanco, G. A., 574
Ban, F., 153
Banck, G., 261
Bankowski, M. J., 1034
Banks, S. M., 999
Barka, N. E., 1312
Barlow, M. A., 1059
Barnes, W., 1221
Barranco, E. A., 45
Bartlett, J. A., 1068
Basham, T., 1006
Bates, J. H., 977
Battaglia, M., 1105
Baudry, B., 1249
Baughn, R. E., 366, 728, 736
Baumgartner, J.-D., 982
Baxter, B. D., 22
Baxter, R., 1023, 1310
Baze, W. B., 1237
Beauchamp, D., 721
Beck-Sague, C. M., 85
Beckius, M. L., 1040
Belbeck, L., 27
Beldjord, K., 430
Bell, E. P., 340
Belle Glade Study Group, 407
Ben Hur, N., 155
Benach, J. L., 1187
Benedetti, J., 653
Benes, C. A., 1036
Bennett, M., 1269
Bennish, M. L., 500
Benson, C. A., 356, 706, 1034
Berardi, V. P., 1203
Bergeron, M. G., 721
Bermudez, L. E., 1262
Bernard, E. M., 348
Berney, P., 281
Bernstein, D. I., 353, 440
Bessen, D., 747
Besuschio, S., 589
Betticher, D. C., 157
Bienzle, U., 1025
Bijlmer, H. A., 1210
Binn, L. N., 7
Birch, C., 326
Blacklow, N. R., 226
Bland, L. A., 85
Blaser, M. J., 626, 1237
Blattner, W. A., 1073
Bloch, A. B., 286
Bodey, G. P., 381, 397
Bodhidatta, L., 1237
Bodmer, M. W., 1148
Bohnsack, J. F., 236
Bonk, S., 108
Boom, W. H., 1216
Borian, F. E., 1099
Borkowsky, W., 108
Boudes, P., 585
Boyce, J. M., 493
Boylen, C. T., 91
Bozeman, L. H., 567
Bradley, A. K., 1112
Bradsher, R. W., 97
Brady, W. E., 938
Brandriss, M. W., 1134
Brazy, P. C., 220
Breiman, R. F., 1257
Brighouse, G., 59
Brightman, V. J., 191
Britt, W. J., 214
Broliden, P.-A., 198
Brommer, M., 353
Bronsdon, M. A., 312
Brown, J., 1210
Brown, P., 467
Brunetti, E., 1290
Brunham, R. C., 531
Bruns, M., 180
Brunt, E. M., 454
Budinsky, A., 52
Budnick, L. D., 340
Bukholm, G., 365
Bunnag, D., 555, 577
Burger, D., 783
Burk, K. H., 1121
Burke, J. F., 79
Burke, R. L., 653
Buschman, E., 634
Byrn, R. A., 1
Calandra, T., 982
Calderone, R. A., 999
Callahan, S. M., 462
Campbell, J. B., 27
Campbell, L. A., 618
Cannon, J. G., 79
Carbon, C., 1042
Carl, M., 791
Carp, R. I., 462
Carr, S. J., 1257
Carter, T., 518
Cassone, A., 1276
Castriciano, S., 124
Castro, K. G., 407
Cate, T. R., 22
Cauthen, G. M., 286
Cavallero, A., 138
Cavarzerani, V., 1013
Cave, M. D., 977
Cervia, J. S., 358
Chambers, H. F., 1170
Chandrashekar, R., 549
Chapman, J., 1023
Chapman, J. R., 910
Chapman, S. W., 343
Charoenpan, P., 577
Chart, H., 343
Chaudhary, R. K., 586
Cheang, M., 531
Cheevers, W. P., 783
Chen, L., 1016
Chernesky, M., 124
Chernow, B., 79
Cheung, A. L., 1177
Chhibber, S., 1033

The Journal of Infectious Diseases 1990;161:1322–1328
© 1990 by the University of Chicago. All rights reserved.
0022–1899/90/6106–0049$01.00

INDEX TO VOLUME 161

Author Index

Aaby, P., 171, 1088
Åberg, H., 942
Abraham, S. N., 1153
Acheson, D. W. K., 134
Ackermann, R., 1203
Agatensi, L., 1276
Agopian, M. S., 1312
Aguero, S. M., 85
Akil, B., 91
Akuffo, H., 775
Al-Qubati, Y., 1309
Alberton, B., 769
Albright, R. E., 1068
Alen, J. C., 1187
Allegra, C. J., 91
Ambrosino, D. M., 922
Amouroux, J., 585
Anderson, J. F., 811
Anderson, L. J., 603, 640
Andersson, J., 903
Andrieu, J. M., 430
Aoki, S., 755
Appel, J., 956
Arbeit, R. D., 230
Archer, D. L., 358
Arduino, M. J., 85
Armstrong, D., 296, 381, 397
Arthur, M., 230
Asano, Y., 1095
Asher, L. V. S., 7
Ashkenazi, S., 961
Ashley, R., 653
Aso, Y., 1128
Assaykeen, T., 1078
Atkins, M., 647
Auclair, P., 721
Augustine, N. H., 236
Azevedo-Bernarda, R., 156
Bøvre, K., 365
Baba, M., 208
Bacha, A., 150
Bacher, J., 755
Baddour, L. M., 1153
Baker, B. A., 1112
Baker, C. J., 65, 917
Ballanco, G. A., 574
Ban, F., 153
Banck, G., 261
Bankowski, M. J., 1034
Banks, S. M., 999
Barka, N. E., 1312
Barlow, M. A., 1059
Barnes, W., 1221
Barranco, E. A., 45
Bartlett, J. A., 1068
Basham, T., 1006
Bates, J. H., 977
Battaglia, M., 1105
Baudry, B., 1249
Baughn, R. E., 366, 728, 736
Baumgartner, J.-D., 982
Baxter, B. D., 22
Baxter, R., 1023, 1310
Baze, W. B., 1237
Beauchamp, D., 721
Beck-Sague, C. M., 85
Beckius, M. L., 1040
Belbeck, L., 27
Beldjord, K., 430
Bell, E. P., 340
Belle Glade Study Group, 407
Ben Hur, N., 155
Benach, J. L., 1187
Benedetti, J., 653
Benes, C. A., 1036
Bennett, M., 1269
Bennish, M. L., 500
Benson, C. A., 356, 706, 1034
Berardi, V. P., 1203
Bergeron, M. G., 721
Bermudez, L. E., 1262
Bernard, E. M., 348
Berney, P., 281
Bernstein, D. I., 353, 440
Bessen, D., 747
Besuschio, S., 589
Betticher, D. C., 157
Bienzle, U., 1025
Bijlmer, H. A., 1210
Binn, L. N., 7
Birch, C., 326
Blacklow, N. R., 226
Bland, L. A., 85
Blaser, M. J., 626, 1237
Blattner, W. A., 1073
Bloch, A. B., 286
Bodey, G. P., 381, 397
Bodhidatta, L., 1237
Bodmer, M. W., 1148
Bohnsack, J. F., 236
Bonk, S., 108
Boom, W. H., 1216
Borian, F. E., 1099
Borkowsky, W., 108
Boudes, P., 585
Boyce, J. M., 493
Boylen, C. T., 91
Bozeman, L. H., 567
Bradley, A. K., 1112
Bradsher, R. W., 97
Brady, W. E., 938
Brandriss, M. W., 1134
Brazy, P. C., 220
Breiman, R. F., 1257
Brighouse, G., 59
Brightman, V. J., 191
Britt, W. J., 214
Broliden, P.-A., 198
Brommer, M., 353
Bronsdon, M. A., 312
Brown, J., 1210
Brown, P., 467
Brunetti, E., 1290
Brunham, R. C., 531
Bruns, M., 180
Brunt, E. M., 454
Budinsky, A., 52
Budnick, L. D., 340
Bukholm, G., 365
Bunnag, D., 555, 577
Burger, D., 783
Burk, K. H., 1121
Burke, J. F., 79
Burke, R. L., 653
Buschman, E., 634
Byrn, R. A., 1
Calandra, T., 982
Calderone, R. A., 999
Callahan, S. M., 462
Campbell, J. B., 27
Campbell, L. A., 618
Cannon, J. G., 79
Carbon, C., 1042
Carl, M., 791
Carp, R. I., 462
Carr, S. J., 1257
Carter, T., 518
Cassone, A., 1276
Castriciano, S., 124
Castro, K. G., 407
Cate, T. R., 22
Cauthen, G. M., 286
Cavallero, A., 138
Cavarzerani, V., 1013
Cave, M. D., 977
Cervia, J. S., 358
Chambers, H. F., 1170
Chandrashekar, R., 549
Chapman, J., 1023
Chapman, J. R., 910
Chapman, S. W., 343
Charoenpan, P., 577
Chart, H., 343
Chaudhary, R. K., 586
Cheang, M., 531
Cheevers, W. P., 783
Chen, L., 1016
Chernesky, M., 124
Chernow, B., 79
Cheung, A. L., 1177
Chhibber, S., 1033

The Journal of Infectious Diseases 1990;161:1322–1328
© 1990 by the University of Chicago. All rights reserved.
0022–1899/90/6106–0049$01.00

Ching, D., 680
Chipowsky, S., 797
Chippendale, G. R., 525
Choi, T.-K., 972
Christensen, G. D., 1153
Christie, B. S., 27
Cilla, G., 152
Clancy, M. N., 809
Clark, H. F., 1099
Clark, J. L., 480
Clark, R. A., 1140
Cleary, K. R., 961
Cleary, T. G., 961
Clements, M. L., 869
Clogston, A. G., 37
Cogger, J., 1262
Cohn, Z. A., 775
Coll, A. M., 150
Comoretto, R., 1013
Concia, E., 1290
Cooper, D., 326
Cooper, M., 1302
Cooper, R. C., 932
Corey, L., 653
Corrado, C., 589
Corsetti, J., 79
Couch, R. B., 22
Cox, J. L., 191
Cozen, W., 1257
Craven, R. B., 878
Crawford, J. T., 977
Crisler, J., 296
Critchlow, C., 653
Cropp, C. B., 878
Cross, A. S., 794, 1148
Crowell, L., 340
Cruess, D. F., 584
Cruz, M., 1194
Cubitt, W. D., 226
Cunningham, A. L., 910
Cunningham, I., 124
Cupps, T. R., 412
D'Costa, L. J., 810
da Costa, C., 156
da Cunha, S., 156
Dahinden, C. A., 242
Dall, L., 1221
Dancis, J., 203
Dankner, W. M., 31
Dasch, G. A., 791
Daum, R. S., 574
Davidson, M., 359
Davies, K. S., 692
Davis, J. P., 97
Davis, R., 91
Davis, T. M. E., 1305
De Bernardis, F., 1276
De Clercq, E., 208
De Montclos, H. P., 367
De Paoli, P., 1013
de Pauw, B., 397
Deardorff, T. L., 146
Decker, M. D., 487
Deinhardt, F., 353
Del Giudice, G., 59
Delahoussaye, P. M., 71
DeLong, E. R., 692
Den Hollander, F., 208
Denis, F., 1309
Denoyel, G.-A., 367
Deny, P., 585
Devlin, C., 124
Di Perri, G., 1290
Dietz, M., 775
Dillner, J., 903
Dinarello, C. A., 79, 888
DiNubile, M. J., 1216
Dobson, M. E., 791
Doebbeling, B. N., 1296
Doherty, R., 326
Donohue-Rolfe, A., 134
Dooley, D. P., 1040
Doua, F., 1309
Drager-Dayal, R., 59
Dreesman, G. R., 1121
Drew, W. L., 1023, 1310
Dropulić, B., 685
Drouet, E. B., 367
Dughetti, S., 1290
Dukes, C. S., 588
Dunn, B. E., 1237
Dunn, R., 230
DuPont, H. L., 18
Duray, P. H., 811
Dutcher, J. P., 647
Dworkin, R. J., 1310
Dwyer, B., 801
Dziobek, L., 493
Eaton, K. A., 1299
Eccles, J., 1112
Echeverria, P. D., 1237
Edelman, R., 356
Edwards, K. M., 487
Edwards, M. S., 65
Eftimiadi, C., 138
Egan, M. L., 236
Eichberg, J. W., 1121
Eijk, P. P., 512
Eisenach, K. D., 977
Eisenstein, B. I., 595
El-Ad, B., 446
El-Farrash, M. A., 1010
El Kholy, A., 1284
Elliott, B., 531
Ellis, R. W., 412
Ellner, J. J., 1284
Eme, D., 430
Emerson, G. W., 1276
Endres, S., 79
Ennis, F. A., 180
Essex, M., 150
Evans, C., 1310
Ewing, W. M., 286
Facklam, R. R., 956
Faden, H., 354
Falkow, S., 582, 1252
Farber, B. F., 37
Farley, M. M., 274
Farr, B. M., 948
Fasth, A., 716
Feilmeier, M. L., 1296
Feinberg, J., 91
Feinstone, S., 647
Feld, R., 381, 397
Feldman, S., 926
Feldmeier, H., 1025
Fenyö, E-M., 198
Feorino, P. M., 567
Ferguson, M. A., 953
Fernandez, E., 430
Ferriani, R., 888
Field, A. M., 343
Fields, B. S., 1257
Filice, C., 1290
Finkelstein, R., 159
Fischetti, V. A., 747, 1177
Fishbein, D. B., 567
Fisher, R. I., 647
Flehmig, B., 865
Fleischmann, J., 143, 809
Fling, M., 1242
Flye, M. W., 454
Follansbee, S., 1078
Foster, D. A., 333
Francioli, P., 281
Francis, H., 1073
Frankel, G., 1252
Frasch, C. E., 932
Freeman, D. J., 185, 191
Fried, M., 155
Friedmann, A., 1252
Friedrich-Jänicke, B., 1029
Függer, R., 1314
Fujita, K., 361
Gajdusek, D. C., 467
Gander, R. M., 711
García-Bengoechea, M., 152
Garcia-Monco, J. C., 1187
Gardeur, D., 585
Garenne, M., 1088
Gary, Jr., G. W., 354
Gaspar, E., 156
Gateley, A., 711
Gaya, H., 397
Gaye, A., 1309
Gayraud, M., 585
Gelfand, J. A., 79
Gemski, P., 794
Gennari, D., 1013
Gennene, M., 988
Gentry, L. O., 807
Gerin, J. L., 412
Germanson, T., 948
Gerna, G., 1105
Gershon, A. A., 661
Giaquinto, C., 198
Gibert, C., 14
Gigliotti, F., 926
Gilligan, P. H., 45
Gillis, J. M., 1
Giron, J. A., 1252
Glauser, M., 397, 982

Glover, A., 647
Golan, J., 155
Gold, J. W. M., 296
Goldstein, R., 230
Goldwasser, E., 348
Goodfellow, K., 1032
Goodwin, C. S., 1302
Gordin, F. M., 14
Gorham, J. R., 783
Goshen, S., 537
Gourde, P., 721
Govindarajan, S., 1116
Gradon, J. D., 1038
Graham, D. J., 647
Graham, F. L., 27
Graninger, W., 1025
Granlund-Edstedt, M., 741
Grant, L., 124
Grau, G. E., 982
Grauballe, P. C., 352
Grayson, L., 801
Grayston, J. T., 127, 618
Green, K. Y., 667
Greenberg, H. B., 18
Greenberg, R. N., 1036
Greene, R. C., 220
Greenwood, B. M., 1210
Greif, W., 922
Griffin, D. E., 449
Groeneveld, K., 512
Groopman, J. E., 888
Gros, P., 634
Guerrant, R. L., 948
Guillevin, L., 585
Günther, B., 1020
Gupta, R. K., 1033
Gust, I., 326
Gwaltney, J. M., 120
Gyorkos, T. W., 769
Haagen, I. A., 266
Haas-Smith, S. A., 412
Hadler, S. C., 407, 647
Håkansson, S., 741
Hall, A. J., 1112
Hall, M. A., 65
Hallander, H. O., 942
Halonen, P., 175
Hamill, R. J., 366
Hamilton, G., 1314
Hamilton, J. D., 220, 1068
Hamilton, R., 728
Hammer, S. M., 1
Hanada, H., 420
Hansen, K., 1194
Hansson, M., 988
Hanto, D. W., 454
Hara, K., 1128
Harada, S., 153, 1010
Harbison, M. A., 1
Harczy, M., 127
Harinasuta, T., 555, 577
Hartley, T. M., 359
Hasty, D. L., 1153
Hausler, Jr., W. J., 153
Haverkos, H. W., 894
Hawley, H. P., 14
Hawley, M. M., 236
Hayashi, J., 426
Heezius, H. C., 266
Heikkilä, E., 1242
Heilman, C. A., 402
Heinricy, U., 865
Hendley, J. O., 120
Henry, S. C., 220, 1068
Herbst, F., 1314
Herndon, B., 1221
Herrmann, J. E., 180, 226
Herwaldt, L. A., 1296
Hibberd, M., 343
Hicks, R., 680
Hill, H. R., 236
Hira, S. K., 584
Hirata, K., 31
Hirsch, G., 814
Hirsch, M. S., 845, 1059
Hjelt, K., 352
Ho, M., 555, 577
Hobbelen, P., 208
Hocine, M., 59
Holdener, T., 1006
Holm, S. E., 741
Holman, R. C., 567
Holmes, K. K., 307
Holzman, R. S., 108
Hoofnagle, J. H., 412
Hook III, E. W., 938
Hopp, P., 1029
Hostetter, M. K., 761
Howard, D. H., 143, 809
Hoy, J., 801
Hudson, R. W., 226
Hueston, L. C., 910
Hughes, A., 1210
Hughes, W. T., 381
Hughlett, C., 91
Hugon, J., 1309
Hull, R., 518
Hull, S., 518
Hultberg, B., 716
Huovinen, P., 41, 1242
Hutton, M. D., 286
Igarashi, K., 250
Ikematsu, H., 426
Inskip, H., 1112
Irving, W. L., 910
Isaacsohn, M., 155
Ishikura, H., 995
Ishimoto, K., 541
Itakura, N., 1095
Iturriza, M., 152
Jacob, J. R., 1121
Jacquillat, C., 430
Jaffe, H. W., 407
Jägdahl, L., 903
Jahkola, M., 1242
Janitschke, K., 1029
Jansen, H. M., 512
Jansen, R. W., 7
Jansen-Rosseck, R., 1025
Jarvis, W. R., 85
Jauregui, E., 449
Jeffery, B., 436
Jeffery, B. S., 1040
Jensen, J. S., 1039
Jessamine, P., 810
Jewell, N. P., 883
Johnson, P. C., 18, 711
Johnson, R. T., 449
Johnson, V. A., 1059
Joly, V., 1042
Jondal, M., 198
Jones, C. C., 653
Josephs, J. A., 1153
Jullien, S., 1042
Juranek, D., 769
Kaiser, D. L., 948
Kajita, Y., 1095
Kajiyama, W., 426
Kale, O. O., 549
Kallin, B., 903
Kallner, A., 942
Kamanga, J., 584
Kaper, J. B., 1249
Kapikian, A. Z., 667
Kaplan, G., 775
Kaplan, J. E., 359, 567
Kaplan, M. H., 37
Kaplan, R., 1034
Kaplan, S. L., 274
Karbwang, J., 577, 1305
Karp, J., 397
Karron, R. A., 647
Karzon, D. T., 487
Kashiwagi, S., 426
Katz, E., 446
Kautter, D. A., 340
Keilhofner, M., 1221
Keitel, W. A., 22
Kelly, N. M., 1148
Kendrick, K. E., 761
Kessler, H. A., 356, 706
Keusch, G. T., 134
Khayat, D., 430
Kida, S., 426
Kiessling, R., 775, 988
Kihara, S., 680
Kikuchi, K., 995
Kikuta, H., 1085
Kilgore, S. G., 364
Kim, C., 230
Kim, Y. S., 462
Kinsella, J. P., 787
Kit, S., 711
Kitamura, T., 1128
Kitzes-Cohen, R., 537
Klastersky, J., 397
Klein, B. S., 97
Klein, J. O., 807, 1055
Klesius, P. H., 108
Klotman, M. E., 220, 1068
Klotman, P. E., 220
Knape, W. A., 236

Kohl, S., 711
Koide, A., 426
Korman, M., 354
Kotilainen, P., 41
Kotloff, K. L., 571
Kraaijeveld, N., 208
Krakowka, S., 1299
Kremsner, P. G., 1025
Krieger, J. N., 307
Kroener, M., 353
Kruszewska, D., 368
Kucik, S., 706
Kumar, V., 1269
Kung, T.-W., 1116
Kuniyoshi, N., 1128
Kuo, C.-C., 618
Kuritsky, J. N., 647
Kurokouchi, K., 420
Kuronen, T., 966
Kwasny, W., 1314
Kwon-Chung, K. J., 809
Ladinsky, M. R., 366
Laga, M., 531
Lai, C.-H., 113
Lai, W. C., 1269
Lairmore, M. D., 359
Lamb, W., 1112
Lambert, P.-H., 59, 982
Lamerson, C. L., 999
Land, S., 326
Landau, W., 1034
Landay, A., 356, 706
Landis, S., 124
Landymore, R. W., 127
Lane, H. C., 91
Lane, J., 1221
Lanford, R. E., 1121
Lang, R., 537
Lange, W. R., 894
Langenberg, W., 507
Lanier, A. P., 359
Lawlor, M. T., 812
Lawrence, H. S., 108
LeDuc, J. W., 7
Lee, J., 755
Lee, S.-D., 1116
Lee, S. H., 555
Leedom, J. M., 91
Leeuwenburg, J., 171
Lemon, S. M., 7
Leónard, G., 1309
Levine, M. M., 571, 1249
Levitz, R. E., 812
Liberski, P. P., 467
Lieb, S., 407
Liebes, L., 203
Lifson, A. R., 436
Lightowlers, M., 134
Lima, N. L., 948
Lin, A. C., 348
Lin, C.-Y., 113
Lin, J.-P., 1262
Lind, K., 1039
Linde, A., 903
Lindvall, A., 903
Link, H., 1194
Linke, M. J., 296
Litwin, C. M., 797
Ljunggren, K., 198
Ljungh, Å., 814
Lo, K.-J., 1116
Logigian, E. L., 1203
Long, S. S., 480
Lonnemann, G., 79
Looareesuwan, S., 555, 577
Lopez-Berestein, G., 562
Lopez, C., 567
Lorenz, J. S., 761
Lorenzini, R., 1276
Lortholary, O., 585
Lory, S., 541
Losonsky, G. A., 330
Lott, I., 926
Lowrance, J. H., 1153
Lowry, P. W., 85
Lozano, P., 956
Lu, H., 1085
Lublin-Tennenbaum, T., 446
Lucas, R., 801
Luchi, M. J., 728
Luke, D. R., 562
Lundin, A., 942
Lutwick, L. I., 1038
Lyhte, L. W., 794
M'Boup, S., 150
Maa, J.-S., 113
Maassab, H. F., 699, 869
Mackow, E. R., 667
MacLean, J. D., 769
Macuacua, R., 584
Madison, B. M., 1153
Magnarelli, L. A., 811
Mahony, J., 124
Maitha, G., 531
Maldonado, M., 1020
Malo, D., 634
Mandell, G. L., 381
Mann, J. M., 1073
Mann, O. E., 127
Marchette, N. J., 680
Marchwicki, R., 7
Markel, A., 159
Marrie, T. J., 127
Marsano, L., 454
Martelli, P., 1013
Mascola, L., 1257
Mason, Jr., E. O., 274
Masters, C. L., 685
Mastro, T. D., 956, 1257
Masuda, T., 1010
Masur, H., 91, 858
Mather, F. J., 574
Mathewson, J. J., 18
Matsumoto, S., 1085
Matsuyama, T., 250
McAllister, C. K., 1040
McCombie, S., 797
McConnell, M. M., 343
McCutchan, J. A., 31
McDade, J. E., 609
McDonald, J. C., 769
McElrath, J., 775
McFarland, L., 364
McGinnis, M. R., 102
McKeough, M. B., 185, 191
McKinley, T. W., 255
McLaughlan, K., 1112
McMahon-Pratt, D., 1313
McMeeking, A., 108
McNeal, M. M., 353, 440
McPhee, D., 326
Mechinaud, F., 755
Medeiros, A. A., 493
Mehalko, S., 1310
Mekalanos, J. J., 1231
Mekthon, S., 1305
Meliço-Silvestre, A., 156
Melish, M. E., 680
Mendoza, S., 203
Menon, A., 1210
Merigan, T. C., 1006
Merrill, D. P., 1059
Mertsola, J., 966
Mertz, G. J., 653
Meurman, O., 175, 966
Meyers, J. D., 381
Michel, S., 367
Michie, H. R., 79
Mijch, A., 801
Mikhael, A., 1269
Miller, G., 833
Miller, P. S., 1225
Miller, R. A., 312
Miller, W. J., 412
Mills, B. J., 647
Mills, J., 1078
Miner, R. C., 1310
Minuth, A. N., 85
Mo, T., 586
Mobley, H. L. T., 525
Molina, J.-M., 888
Molunto, P., 1305
Monack, D., 582
Monath, T. P., 878
Monto, A. S., 333, 781
Mordhorst, C. H., 618
Moreno, M., 1020
Morgan, D. R., 1299
Morris, D. J., 149
Morris, Jr., J. G., 571
Morse, D. L., 340
Mortimer, Jr., E. A., 473
Morton, W. R., 312
Moschese, V., 198
Murphy, B. R., 869
Murphy, P. C., 7
Murphy, R., 706
Murray, B. E., 54, 961
Murray, H. W., 358, 992, 1041
Murray, P. R., 454
Murray, R. A., 85
Musher, D. M., 366, 728, 736

Musser, J. M., 130
Mwansa, N., 584
N'Gaporo, I., 1309
Naclerio, R. M., 120
Naficy, A. B., 1041
Nafziger, D. A., 155
Nakashima, K., 426
Narvaiz, M., 589
National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group, 661
Ndinya-Achola, J. O., 531
Nedenskov-Sørensen, P., 365
Nelson, J. A., 1034
Ness, M. J., 808
Newton, B. J., 1034
Ngeleka, M., 721
Nicole, A., 157
Nightingale, C., 812
Nikoskelainen, J., 41
Nishioka, M., 420
Noguchi, A., 426
Nomura, H., 426
Norden, C. W., 52
Norrby, S. R., 716
Novotny, P., 581
Nowak, N. A., 226
Nurre, S., 296
Nyman, M., 261
Nzilambi, N., 1073
O'Malley, P. M., 436
O'Rourke, E. J., 102
Ogata-Arakaki, D., 91
Ogunrinade, A. F., 549
Ohmit, S., 781
Okabe, N., 153
Oldberg, Å., 814
Opal, S. M., 493, 794, 1148
Orren, A., 932
Osborne, B. M., 71
Österberg, E., 942
Otsuka, H., 711
Ottenheijm, H., 208
Ottenhoff, T., 988
Oudbier, J. H., 507
Owusu, I., 1269
Oya, A., 153
Ozaki, T., 1095
Padian, N. S., 883
Pakes, S. P., 1269
Paladin, F., 175
Palardy, J. E., 1148
Pane, J., 436
Pao, C. C., 113
Paparello, S., 791
Parea, M., 1105
Parisi, J. T., 1153
Parker, R. A., 640
Parkinson, D., 647
Patel, Y., 932
Pauwels, R., 208
Pavia, A. T., 255
Pavlovsky, S., 589
Peeples, M. E., 1034
Peglow, S. L., 296
Perez-Perez, G. I., 1237
Pérez-Trallero, E., 152
Perfect, J. R., 588
Perine, P. L., 584
Peris, A., 152
Perrillo, R. P., 454
Perron-Henry, D. M., 226
Peter, J. B., 1312
Peterson, K. E., 806
Peterson, L., 806
Peterson, L. R., 806
Pfisterer, M., 865
Phair, J., 296, 706
Pickering, L. K., 961
Ping, L.-H., 7
Pinkston, P., 1
Piot, P., 531, 1073
Pirola, F., 1290
Pisa, P., 988
Pisarik, L., 1042
Pizzo, P. A., 316, 381, 397, 755
Plos, K., 518
Plotkin, B. J., 364
Plotkin, S. A., 1099
Plourde, P., 810
Plummer, F. A., 531, 810
Pogue, C. L., 296
Poland, J. D., 878
Pottage, Jr., J. C., 356, 706
Potter-Bynoe, G., 493
Potter, P. C., 932
Pramberg, J. C., 574
Preus, L., 761
Prevec, L., 27
Price, M. F., 807
Prince, A., 541
Pritchard, D. G., 236
Proud, D., 120
Pugin, P., 157
Puhr, N. D., 255
Pukrittayakamee, S., 1305
Quinn, T. C., 1073
Quinti, I., 198
Quintiliani, R., 812
Ramirez, M. T., 153
Ratnamohan, V. M., 910
Rauws, E. A. J., 507
Rayner, A. A., 647
Raza, A., 127
Reagan, D. R., 155
Reber, A.-M., 242
Regamey, C., 157
Reichart, C. A., 938
Rekart, M. L., 692
Remington, J., 397
Rench, M. A., 65
Rey, J. L., 1309
Reymann, M., 330
Reynaud, P., 1032
Richer, G., 769
Richman, D. D., 31
Riley, L., 1252
Rios, C. D., 1006
Riser, B. L., 699
Ritz, W. J., 45
Robbins, J. B., 821
Roberson, P. K., 926
Robinson, J., 1302
Robinson, M. M., 783
Rocha, R. M., 1025
Rogy, M., 1314
Roingeard, P., 150
Ronald, A. R., 810
Roncoroni, A. J., 589
Rose, R. M., 1
Rosenblum, L. S., 407
Ross, I. K., 1276
Rossi, G. A., 138
Rossi, P., 198
Rotbart, H. A., 787
Roth, Y., 446
Rowe, B., 343
Rowe, N. H., 185, 191
Rubin, M., 755
Rudensky, B., 155
Rutherford, G. W., 436
Ruuskanen, O., 966
Ruutu, P., 175
Ryan, K. J., 797
Rydén, C., 814
Sacco, O., 138
Sachdeva, M., 1170
Sacks, S. L., 692
Sadallah, F., 59
Sadé, J., 537
Sadoff, J. C., 1148
Safrin, S., 1078
Saikku, P., 618
Saiman, L., 541
Saini, S. S., 999
Sakaguchi, M., 888
Salkin, I. F., 102
Salo, R. J., 1225
Sam, E., 680
Sanderlin, K. C., 567
Sandland, M., 801
Sangare, A., 1309
Santini, G., 1013
Sarasini, A., 1105
Sassou-Guesseau, E., 1309
Sato, N., 995
Sattler, F. R., 91
Savarino, S. J., 1249
Sawada, T., 426
Schanen, A., 367
Schauf, V., 1225
Schellekens, J., 982
Schemper, M., 1314
Schiff, G. M., 353, 440
Schimpff, S. C., 381
Schindler, R., 888
Schlesinger, J. J., 1134
Schneerson, R., 821
Schneider, G., 1210
Schols, D., 208
Schoolnik, G. K., 1252
Schultz, S., 340

Schulz, F., 1314
Schurr, E., 634
Schwalbe, R. S., 45
Schwartz, T., 446
Sears, S. D., 869
Seidelman, W., 124
Selander, R. K., 130, 230
Sell, S. H., 487
Sellers, P. W., 692
Sellin, M., 741
Sellors, J., 124
Septimus, E. J., 363, 816
Seto, W.-H., 972
Settergren, B., 716
Shaunak, S., 1068
Shelhamer, J., 91
Shenep, J. L., 381, 926
Shenton, F., 1112
Sherwood, J. R., 353, 440
Shiboski, S. C., 883
Shimizu, R. Y., 809
Shipman, L. D., 255
Shirai, M., 420
Shukla, R., 353, 440
Siber, G. R., 922
Siitonen, E. H. A., 1242
Simpson, W. A., 1153
Six, H. R., 22
Skamene, E., 634
Smith, J. D., 255
Smith, P. D., 999
Smulian, A. G., 296
Snoeck, R., 208
Snyder, M. H., 869
Snydman, D. R., 647
Söder, O., 988
Sohmer, P. R., 436
Søndergård-Anderson, J., 1039
Sood, S. K., 574
Soong, Y.-K., 113
Soubrane, C., 430
Southwick, F. S., 1216
Spector, S. A., 31
Spika, J. S., 956, 1257
Spinola, S. M., 336
Spira, T. J., 567
Spitzer, E. D., 454
Spruance, S. L., 185, 191
Stanford, G. G., 79
Stanley, A., 436
Stanley, M., 436
Stapleton, J. T., 7
Stead, W. W., 286
Steere, A. C., 1203
Steinberg, S. P., 661
Stephens, D. S., 274
Sternberg, N., 155
Steutermann, D., 1269
Stevens, C., 307
Stewart, I., 124
Stewart, J. C. B., 185, 191
Stiver, H. G., 692
Storch, G. A., 454
Storm, A., 797
Strikas, R. L., 640
Strockbine, N., 1252
Strosselli, M., 1290
Struelens, M., 500
Suga, S., 1095
Sullivan, K. M., 333
Sullivan, M. C., 812
Sullivan, P. A., 1276
Sun, D., 1231
Sundström, L., 1242
Supanaranond, W., 1305
Svanborg-Edén, C., 518
Svec, F., 1032
Swack, N. S., 153
Swenson, J. M., 85
Swiss-Dutch J5 Immunoglobulin Study Group, 982
Tacket, C. O., 356
Takahashi, M., 1095
Takahashi, S., 995
Tall, B. D., 571
Taniguchi, K., 667
Tardif, D., 721
Tauxe, R. V., 255
Taylor, D. G., 7
Taylor, D. N., 1237
Taylor, R. K., 1231
Teele, D. W., 807
Teklemariam, S., 775
Telzak, E. E., 340
Thirumoorthi, M. C., 590
Thom, D. H., 618
Thomas, J. R., 454
Thompson, C., 922
Thore, M., 261
Tibbs, C. W., 791
Ting-Chou, C., 1059
Ting, L.-P., 1116
Tobinai, K., 153
Tochner, Z., 446
Todd, J. K., 953
Todeschini, G., 397
Tomizawa, K., 1085
Tompkins, R. G., 79
Tonetti, M., 138
Toossi, Z., 1284
Torre, D., 1105
Torres, C., 175
Torsellini, M., 1105
Tourani, J. M., 430
Trees, D. L., 336
Treloar, G., 326
Trenholme, G. M., 1034
Trollfors, B., 716
Tsai, Y.-T., 1116
Tuazon, C. U., 91
Tupasi, T. E., 175
Tylewska-Wierzbanowska, S. K., 368
Tytgat, G. N. J., 507
Uldum, S. A., 1039
Upchurch, D. M., 938
Urbanski, P., 706
Vadiei, K., 562
Vaisberg, A., 449
Valkenburg, H. A., 1210
Valmassoi, J., 1252
van Alphen, L., 512, 1210
Van Boeckel, C., 208
Van Dedem, G., 208
van der Meer, J. W. M., 79
van der Sande, W. J. M., 932
Van Savage, J., 487
Vannier, E., 888
Varner, T. L., 692
Vartian, C. V., 363, 816
Vaughan, W. P., 808
Verbrugh, H. A., 266
Vercauteren, G., 1073
Verdegem, T. D., 91
Verdier, M., 1309
Vergeront, J. M., 97
Verhoef, J., 266, 397, 982
Verkooyen, R. P., 266
Verma, P. R., 45
Vial, P. A., 571
Vial, P., 1249
Victor, G. H., 1148
Viljanen, M. K., 966
Villar, B. F., 1187
Visonneau, S., 430
Visschers, G., 512
Vivaldi, E., 1020
Volkman, D. J., 412
Vugler, L. G., 214
Wade, J. C., 381, 397
Wahl, L. M., 999
Wahl, S. M., 999
Wahren, B., 198, 903
Wainberg, M. A., 810
Walker, M. C., 353
Walport, M. J., 555
Walsh, E. E., 1134
Walsh, T. J., 755
Walzer, P. D., 296
Wamola, I. A., 810
Wang, S.-P., 127, 618
Wanger, A. R., 54
Ward, B. J., 449
Ward, P. H., 1020
Ward, R. L., 353, 440
Warfield, D. T., 567
Wasan, K. M., 562
Wasserman, R. L., 787
Watanabe, S., 420
Watson, D. A., 728, 736
Wattanagoon, Y., 555
Weeks, K. E., 1203
Weil, G. J., 549
Weil, M., 430
Weinke, T., 1029
Weisfuse, I. B., 647
Weiss, G. R., 647
Welkon, C. J., 480
Wells, J. G., 255
Wendel, M., 814
Wenerstrom, G., 185, 191
Wenzel, R. P., 155
West, K., 180

White, Jr., A. C., 1313
White, N. J., 555, 577, 1305
Whittle, H., 1112
Wiktor, S. Z., 1073
Wilber, J. C., 436
Will, M., 647
Willoughby, A., 14
Willoughby, R. E., 116
Wilmore, D. W., 79
Wilson, C., 1284
Wilson, C. M., 102
Wilson, D., 203
Winder, A., 446
Windus, D. W., 454
Winsor, Jr., D. K., 366
Wojtyniak, B. J., 500
Wolff, A., 467
Wolff, S. M., 79
Wolner-Hanssen, P., 307
Wongsrichanalai, J., 1237
Woods, G. L., 808
Wu-Hsieh, B. A., 143
Wu, J.-C., 1116
Wu, M.-M., 982
Wu, S.-Y., 113
Xu, J.-K., 1302
Yacoub, A., 814
Yagihashi, A., 995
Yamamoto, T., 361
Yamanishi, K., 1095
Yamaoka, K., 175
Yanagi, K., 153
Yang, K. D., 236
Yang, W., 1016
Yau-Young, A. O., 1262
Yazaki, T., 1095
Yeni, P., 1042
Yip, A. W.-C., 972
Yogo, Y., 1128
Yokota, T., 361
Yolken, R. H., 116
Yoshikawa, T., 1095
Young, E. C., 353, 440
Young, L. S., 381, 397, 1262
Yow, M. D., 149, 381
Yuen, K.-Y., 972
Zachoval, R., 353
Zanen, H. C., 512, 1210
Zimmerli, W., 242
Zotter, G. M., 1025

Subject Index

Acyclovir, for
  herpes simplex labialis, 185
  meningoencephalitis, due to HSV-2, resistance, 711
Adenovirus, vaccine, recombinant, against rabies, 27
Adherence
  E. coli, uropathogenic, DNA homology in, 518
  P. aeruginosa, to respiratory epithelium, 541
  P. mirabilis, 525
  staphylococcal, to peritoneal mesothelial cells, 266
  S. aureus, role of fibrinogen, 1177
  V. parahaemolyticus, to human ureteral mucosa, 361
Aeromonas hydrophila, soft-tissue infection, 816
AIDS
  and acyclovir-resistant HSV, treatment with foscarnet, 1078
  and CMV, adrenal hypertrophy in, 585
  and disseminated cat-scratch disease, 71
  and fungal cholecystitis, 358
  bacteremia due to *M. avium-intracellulare*, treatment for, 801
  C. parvum infection, treatment with dialyzable leukocyte extract, 108
  Commentary, pediatric AIDS, 316
  decreased susceptibility of HIV isolates to zidovudine, 326
  HIV-1 isolation from monocytes, 706
  in neonates born to HIV-infected mothers, 198
  meningoencephalitis, due to HSV-2, resistance to acyclovir, 711
  pathogenesis, 888, 1010
  pediatric, AIDS Commentary, 316
  prodromal porphyria, 1032
  vaccine, ethical issues in volunteer studies, 356
Alcohol, Drug Abuse, and Mental Health Administration, summary, infections among iv drug users, 894
Amebiasis, due to *E. histolytica*, epidemiology, 1029
Aminoglycosides, liposome-encapsulated, for *M. avium-intracellulare*, in mice, 1262
Amoxicillin, prophylaxis, for experimental streptococcal endocarditis, 281
Amphotericin B
  induced malignant hypertension, 588
  liposomal, nephrotoxicity in diabetic rats, 562
  possible association with broncholitis obliterans, 589
  reduced erythropoietin response to anemia, 348
  reduced toxicity by empty liposomes, 1042
Ampicillin/sulbactam, for osteomyelitis due to *S. aureus*, 52
Anemia, due to parvovirus, 604
Animal model
  candidiasis, granulocytopenic rabbits, 755
  experimental cryptosporidiosis, in macaques, 312
  influenza virus, ferret, 699
  murine LP-BM5 retrovirus–induced immunodeficiency, 1006
  P. aeruginosa infection, anti-TNFα monoclonal antibody, 1148
Anisakiasis, detection by microELISA, 995
Antibiotic resistance to
  ciprofloxacin, in coagulase-negative staphylococci, 45
  vancomycin, in *S. haemolyticus*, 45
Antibiotics
  activity against *S. aureus*, 1023
  β-lactam, binding in methicillin-resistant *S. aureus*, 1170
Antibody
  neutralizing, persistence after smallpox vaccination, 446
  oligoclonal *B. burgdorferi*–specific, in CSF, 1194
Antibody to
  B. burgdorferi, intrathecal response, as diagnostic test, 1203
  CMV, in mothers and neonates, 214
  H. influenzae, type b, 922
  HIV
    in neonates born to HIV-infected mothers, 198
    test, 436
  HTLV-I, in patients with leprosy, 1309
  inactivated influenza vaccines, 333
  P. carinii, measurement by immunoblotting, 296
  $p40^{tax}$ protein in HTLV-I, 426
  pertussis, 473, 480, 487
  rotavirus, 440
  TNFα, murine, monoclonal, 1148
  V. cholerae pili, as protection against cholera, in infant mouse, 1231
Antimicrobial agents, clinical trials in neutropenic patients, 397
Arbovirus, neurotropic, in vitro, in mice, 685
Arcanobacterium haemolyticum, penicillin tolerance in, 261
Arteriovenous graft infections, due to *M. chelonae*, 85
Astrovirus, gastroenteritis, diagnosis by antigen detection, 226
AZT (*See* zidovudine)

Bacteremia, due to
  K. pneumoniae, from handfishing injury, 155
  P. acidilactici, 956
β-lactamase, enterococcal and staphylococcal, 54
β-lactam antibiotics, alternative lysozyme-dependent activity, 250
Blastomyces dermatitidis, acute infection, assay of cellular immunity, 97
Blastomycosis, outbreak, assay of cellular immunity, 97
Blastoschizomyces capitatus, meningitis, treatment for, 1041
Bordetella pertussis
  antibody after infection vs. immunization, 480
  in HIV infection, 1296
Bordetella species, infection, pathogenesis, 581, 582
Borrelia burgdorferi
  and *I. dammini*, epidemiology, 811
  antibody detection, 1034
  antibody in CSF, 1194
  early invasion of CNS, 1187
  false-positive IgM antibody in ELISA, due to IgM rheumatoid factor, 1312
  intrathecal antibody, as diagnostic test, 1203
Brazilian purpuric fever, evolutionary genetic relationships of *H. influenzae*, 130
Broncholitis obliterans, and amphotericin B, 589

Campylobacter pylori (*See also Helicobacter pylori*)
  genetic transformation, 365
  transmission by gastroduodenoscopy, 507
Candida albicans
  disseminated infection, chemotherapy for, 755
  GM-CSF and monocyte activity, 999
  iC3b receptor, 761
  phagocytosis, 761
  role of aspartate proteinase, in vulvovaginal candidiasis, 1276
Candida, antigen latex test, 807, 808
Candidiasis
  disseminated, chemotherapy for, 755
  role of aspartate proteinase, in vulvovaginal infection, 1276

The Journal of Infectious Diseases 1990;161:1329–1335
© 1990 by the University of Chicago. All rights reserved.
0022-1899/90/6106-0050$01.00

Cat-scratch disease
abdominal visceral granulomas, 71
atypical, diagnostic use of Warthin-Starry stain, 71
CD16, as serum marker of disease progression in HIV, 430
CD4
recombinant, effect on HIV infection of monocyte/macrophage, 1
soluble, synergism and inhibition of replication of HIV, 1059
Cellulitis, due to group A streptococci, treatment with clindamycin, 155
Central nervous system
early invasion by *B. burgdorferi*, 1187
infection, due to arbovirus, 685
Chlamydia pneumoniae
endocarditis, 127
strain TWAR, 618
Chlamydia trachomatis, diagnosis, by detection of antigen in urine, 124
Chloroquine, for hyperreactive malarial splenomegaly syndrome, 157
Cholera, antibody to *V. cholerae* pili, in infant mouse, 1231
Chronic obstructive pulmonary disease, *H. influenzae* infection, 512
Ciprofloxacin
for malignant external otitis, 537
resistance, emergence in coagulase-negative staphylococci, 41
Clindamycin, effect on glycocalyx production by viridans streptococci, 1221
Clostridium botulinum, type E, outbreak, due to uneviscerated fish, 340
Clostridium perfringens, bacteremia, associated with hypoglycemia, 1038
Colds, due to rhinovirus, kinin generation in nasal secretions, 120
Colpitis macularis, isolates of *T. vaginalis*, 307
Coxiella burnetii, Q fever, mode of transmission, 368
Cryptococcosis, in AIDS, 809
Cryptococcus neoformans gattii, infection in AIDS, 809
Cryptosporidiosis
experimental, in nonhuman primates, 312
in AIDS, treatment with dialyzable leukocyte extract, 108
Cryptosporidium, infection, in primates, 312
Cryptosporidium parvum, infection, in AIDS, treatment with dialyzable leukocyte extract, 108
Cystic hydatid disease, percutaneous drainage in, 36
Cystitis, in women, treatment with trimethoprim, 942
Cytomegalovirus
antibodies in mothers and neonates, 214
congenital infection, preventive strategies, 149
detection by PCR, in mice, 220
diagnosis in organ transplant recipients, 454
dual infection with HHV-6, 910
human, localization by in situ hybridization, in peripheral blood leukocytes, 3
infection, in organ transplant recipients, 454
survival in stored blood, 1310

Dialysis patients, infections due to *M. chelonae*, 85
Dialyzable leukocyte extract, for *C. parvum* infection, in AIDS, 108
Diarrhea due to
C. parvum, treatment with dialyzable leukocyte extract, 108
Shigella species, 500
Diarrhea
etiology, in community-acquired pediatric illness, 571
nosocomial, risk for urinary tract infection, 948
Dimethyl sulfoxide, for HSV, 191
Drug use, illicit, and infectious diseases, 894

Echinococcus granulosis, hydatid liver cysts, human, 1290
Edwardsiella tarda, soft-tissue infection, 816
Ehrlichia canis, in human ehrlichiosis, 609
Ehrlichiosis, animal and human, due to *E. canis*, 609
Endocarditis
due to *C. pneumoniae*, culture-negative, 127
due to viridans streptococci, clindamycin inhibition of glycocalyx production, 1221
prosthetic valve, due to methicillin-resistant *S. aureus*, 812
streptococcal, prophylaxis with amoxicillin, 281
Endotoxin
and nephrotoxicity of aminoglycosides, 721
in intraabdominal infection, 1314
Entamoeba histolytica, prevalence and clinical importance in risk groups, 1029
Enterovirus, meningoencephalitis, detection by PCR, 787
Enzyme-linked immunosorbent assay (ELISA)
to detect
and quantitate Shiga toxin and Shiga-like toxin II, 134
astrovirus in stool, 226
to diagnose
EBV mononucleosis, 903
pertussis, 966
Epidemiology
B. dermatitidis infections, outbreak in Wisconsin, 97
botulism type E outbreak, due to uneviscerated fish, 340
C. pylori, transmission by gastroduodenoscopy, 507
diarrhea, community-acquired, in children, 571
E. histolytica, prevalence and clinical importance in risk groups, 845
H. pylori, seroprevalence, in Thailand, 1237
hepatitis A virus, outbreak, among cancer patients, 647
hepatitis B virus
childhood infection, in The Gambia, 1112
heterosexual transmission, 407
hepatitis delta virus
correlation of serum delta RNA with clinical course, in Taiwan, 1116
in iv drug users, in Spain, 152
prevalence in HBV carriers, 1116
regional variation, in Senegal, 151
HHV-6, prevalence in Japan, 153
HIV
and hepatitis A in hospital admissions, 14
transmission, in heterosexuals, 883
HIV-1
and HTLV-I, risk factors for, in Zaire, 1073
risk factors for, in The Gambia, 584
HTLV-I
antibody, in patients with leprosy, 1309
antibody prevalence, in Alaskan natives, 359
L. pneumophila, role of air sampling, 1257
Lyme disease, prevalence, in Philadelphia, 811
M. chelonae infection, risk factors for, in a hemodialysis clinic, 85
measles
exposure and mortality, in Senegal, 1088
transmission and severity, in Kenya, 171
meningitis, due to *H. influenzae*, in Gambian children, 1210
microbial, for diagnosis of infectious diseases, 595
molecular, *S. sonnei*, 797
N. salmincola, transmission by handling infected fish, 146
parainfluenza virus, pediatric infection, 640
pertussis, transmission, 473, 480
RSV
pediatric infection, 640
subtypes in a community population, 781
S. epidermidis, nosocomial infection, 493
shigellosis, in Bangladesh, 500
toxoplasmosis, outbreak in pregnant women, 769
tuberculosis, nosocomial transmission, 286

viral lower respiratory tract infections, in Filipino children, 175
Epstein-Barr virus
detection by peptide ELISA, in mononucleosis, 903
infection, role of γδ lymphocytes, 1013
latency and replication, 833
Errata
Pocchiari et al., J Infect Dis 1989;160:795–802, 591
Hughes et al., J Infect Dis 1990;161:381–396, 1316
Erythropoietin, reduced response to anemia by amphotericin B, 348
Escherichia coli
clonal nature of urinary tract infection, 230
enteroaggregative, DNA probe for, 1249
evolutionary divergence, 230
O114:H21, new putative colonization factor, 343
uropathogenic, DNA homology in, 518
virulence, relation to aerobactin and hemolysin production, 794
Ethical issues, volunteers in AIDS vaccine trials, 356
Eulogy, Edward H. Kass, M.D., 1055

Falciparum malaria, treatment with quinine, consecutive-infusion regimen, 1305
Fever
in neutropenic patients, 381, 397
unexplained, 381
Fibrinogen, role in *S. aureus* binding to catheters, 1177
Fibronectin, effect on IgA-mediated uptake of group B streptococci by phagocytes, 236
Flavivirus, yellow fever virus, immunogenic properties of purified proteins, 1134
Fluconazole, for disseminated candidiasis, 755
Foscarnet, for acyclovir-resistant HSV in AIDS, 1078
Fungal cholecystitis, and AIDS, 358
Fungal infection, due to *S. inflatum*, 102

Gardnerella vaginalis, bacteremia, 367
Gastritis, due to *H. pylori*, 626
Gastroenteritis, due to
astrovirus, diagnosis by antigen detection, 226
rotavirus
immune protection of infants, 1099
in infants and children, serologic response, 1105
Genital tract infection, due to
HSV, treatment with interferon-α, 692
HSV-2, 653
Gentamicin, resistance in *K. pneumoniae*, 1033
Glomerulonephritis, with dysentery due to *S. flexneri*, 366
Gonorrhea, maternal risk factor for low birth weight, 531
Granulocyte-macrophage colony-stimulating factor, and monocyte activity against *Candida*, 999
Group A streptococci
cellulitis, treatment with clindamycin, 155
IgG receptor, human, 747
Group B streptococci
buoyant-density subpopulations, characterization, 741
effect of fibronectin on IgA-mediated uptake by phagocytes, 236
enhanced killing by penicillin and opsonophagocytosis, 1225
immunization, 917
meningitis, immune response in infants, 65

Haemophilus ducreyi, genital ulcer disease and HIV-1, 810
Haemophilus influenzae aegyptius, Brazilian purpuric fever, evolutionary genetics, 130
Haemophilus influenzae
meningitis, in Gambian children, 1210
reinfections in chronic obstructive pulmonary disease, treatment, 512
type b
adherence to human cells, 274
antibody response, light chain ontogeny, 922
conjugate vaccine, 574
conjugate vaccine, risk in immunocompromised children, 926
Hansenula fabianii, prostatitis, 1040
Helicobacter pylori
intracellular vacuolization due to urease, 1302
peptic ulcer disease, pathogenesis, 626
persistence, in conventionalized piglets, 1299
seroprevalence, in Thailand, 1237
Hemadsorption, in piliated *H. influenzae* type b, 274
Hemophilus influenzae (*See Haemophilus influenzae*)
Hemorrhagic fever with renal syndrome, abnormal T cell immunoregulation, 1016
Hepatitis A virus
and hepatitis B virus, simultaneous vaccination, 865
in vivo replication, reversion of antigenic variant to wild type, 7
outbreak, among cancer patients, 647
serology and IFN production in early infection, 353
transmission via serum, 647
vaccine, immunogenicity, 586
Hepatitis B virus
antigen carriers, asymptomatic, with hepatitis delta virus antibodies, 150
heterosexual transmission, 407
in vitro immune reponse to surface antigens, 412
infection, pattern in childhood, in The Gambia, 1112
recombinant core antigen, 420
Hepatitis delta virus
antibodies, in asymptomatic carriers of hepatitis B surface antigen, 150
in HBV carriers, correlation of serum delta RNA with clinical course, 1116
in iv drug users, in Spain, 152
Hepatitis virus, non-A, non-B, expression of infectious particles, 1121
Herpes simplex labialis, treatment with
acyclovir, 185
idoxuridine, 191
Herpes simplex virus
and AIDS, treatment with foscarnet, 1078
genital infection, treatment with topical interferon-α, 692
treatment with acyclovir, 185
treatment with idoxuridine, 191
Herpes simplex virus, type 2
genital, transmission, 653
resistance to acyclovir, in AIDS, 711
vaccine, efficacy, 653
Herpesvirus, varicella zoster virus, severity and clinical findings, in children, 1095
Histoplasma capsulatum, role of human macrophages treated with rIFN-γ, 143
Histoplasmosis, role of human macrophages treated with rIFN-γ, 143
Human herpesvirus 6
and HIV infection, 567
dual infection with CMV, 910
enhanced replication in human lymphocytes by MAb to CD3, 1085
prevalence in Japan, 153
Human immunodeficiency virus
and HHV-6 infection, 567
antibody
in commercial gamma globulin, 153
in neonates born to HIV-infected mothers, 198
chemotherapy, 845

decreased susceptibility in vitro to zidovudine, 326
effect of rCD4 on monocyte/macrophage infection, 1
food counseling in infection, 358
infection, and pertussis, 1296
infectivity of variants, 1010
inhibition of replication
by zidovudine, CD4, and rIFN-αA, 1059
in vitro, 208
monocyte/macrophage function after infection, 888
opportunistic infection, management, 858
PCR and antibody test for, 346
soluble CD16 titers in serum, 430
T-helper lymphocytes as marker for immune status, 356
transmission, in heterosexuals, 883
type 1
and genital ulcer disease, 810
and HTLV-I, risk factors for, in Zaire, 1073
detection of proviral sequences by PCR, 1068
isolation
by differential culture techniques, 706
from monocytes, 706
provirus, correlation with neurologic disease, 1068
risk factors for, in The Gambia, 584
Human T lymphotropic virus type 1
and HIV-1, risk factors for, in Zaire, 1073
antibody
in patients with leprosy, 1309
prevalence, in Alaska, 359
to $p40^{tax}$ protein and infectivity, 426
infectivity and antibody to $p40^{tax}$ protein, 426
Hybridization, in situ, to localize CMV, 31
Hypoglycemia, associated with *C. perfringens* bacteremia, 1038
Hypoglycemia-hyperinsulinemia, in scrapie-injected hamster, 462

Idoxuridine, for herpes simplex labialis, 191
Infectious Diseases Society of America
annual meeting program, preliminary information, 1045
antimicrobial agents in febrile neutropenic patients, 381
dates for applications for postdoctoral fellowship training programs, 161, 370
meeting presentation
C. pneumoniae, strain TWAR, 618
EBV, latency and replication, 833
ehrlichiosis, 609
H. pylori, 626
HIV, chemotherapy, 845
HIV, opportunistic infection, management, 858
microbial epidemiology, molecular techniques, 595
parvovirus, human, 603
vaccine, capsular polysaccharide-protein conjugate, 821
IgG
serology for onchocerciasis, 549
to *S. pneumoniae* cell wall polysaccharide, 736
Immune response, to
group B streptococci, in infants surviving meningitis, 65
rotavirus, in neonates, 330
Immunocompromised Host Society, clinical trials on antimicrobial management of neutropenic patient, 397
Immunoglobulin, iv, synergism with penicillin, effect on group B streptococci, 1225
Impetigo, relation to Fc receptors, group A streptococci, 747
Infection control, efficacy of universal precautions, 14
Infectious diseases, and iv drug use, 894
Influenza A virus, treatment with rimantidine, in mice, 180
Influenza B virus, vaccine
attenuation, immunogenicity, efficacy, 22
efficacy, in adult volunteers, 869
Influenza virus
vaccine, antibody response, 333
wild-type and cold-adapted, effect on macrophage, 699
Interferon
activation, during hepatitis A virus infection, 353
prognostic value, in septic shock, 982
Interferon-α
and neopterin, in measles, 449
with nonoxynol-9, for genital herpes simplex virus infection, 692
Interferon-αA, recombinant, synergism and inhibition of replication of HIV, 1059
Interferon-γ
for leishmaniasis, 992
human recombinant, role in macrophage activation against *H. capsulatum*, 143
Interleukin, prognostic value, in septic shock, 982
Interleukin-1, and TNF in septic shock and endotoxin fever, 79
Interleukin-2, recombinant, induction of cellular immunity in leishmaniasis, 775
Ixodes dammini, and *B. burgdorferi*, epidemiology, 811

Japanese encephalitis virus, vaccine, efficacy, 878
JC virus, urinary excretion, in older patients, 1128

Kass, Edward H., eulogy, 1055
Kawasaki syndrome, pathogenesis, 680
Klebsiella pneumoniae
bacteremia, due to handfishing injury, 155
gentamicin resistance, 1033

Legionella pneumophila, epidemiologic investigation, role of air sampler, 1257
Leishmania, amastigotes, reduced by rIL-2 injection, 775
Leishmania donovani
purified protein vaccine, 1313
treatment with IFN-γ, 992
Leishmaniasis
disseminated cutaneous, treatment with rIL-2, 775
purified protein vaccine, 1313
TNF levels in, 988
treatment with IFN-γ, 992
Leprosy
and HTLV-I, 1309
TNF levels in, 988
Liposomes, to prevent amphotericin B toxicity, 1042
Lower respiratory tract infection, viral, in Filipino children, 175
Lyme disease
antibody detection, 1034
antibody to *B. burgdorferi*
in CSF, 1194
intrathecal, 1203
early CNS invasion by *B. burgdorferi*, 1187
prevalence, in Philadelphia, 811
Lymphocyte
activation in malaria, 1025
γδ, in EBV infection, 1013
T
cytotoxic, effect of rimantidine on, 180
immunoregulation in HFRS, 1016
percentage as marker for immune status, 356

Macrophage, alveolar
effect of influenza virus on, 699

inhibition by short-chain fatty acids, 138
function, in HIV infection, 888
pulmonary alveolar, effect of rCD4 on HIV infection, 1
treated with rIFN-γ, role in immunity against *H. capsulatum*, 143
Malaria
hyperreactive malarial splenomegaly syndrome, treatment with chloroquine, 157
lymphocyte activation in infection, 1025
P. falciparum
mortality after poor response to quinine, 577
splenic Fc receptor function in, 555
Measles
exposure and mortality, in Senegal, 1088
IFN-α and neopterin in, 449
transmission and severity, in Kenya, 171
Meningitis, due to
B. capitatus, treatment, 1041
group B streptococci, immune response in infants, 65
H. influenzae, in Gambian children, 1210
M. tuberculosis, diagnosis by adenosine deaminase activity, 156
meningococci, penicillin prophylaxis for, in complement deficiency, 932
Meningoencephalitis, due to
enterovirus, detection by PCR, 787
HSV-2, resistance to acyclovir, in AIDS, 711
Mesothelial cells, peritoneal, adherence by staphylococci, 266
Microenzyme-linked immunosorbent assay, to detect anisakiasis, 995
Minocycline, for endocarditis, due to methicillin-resistant *S. aureus*, 812
Monoclonal antibody, to *S. typhi* flagellin, for diagnosis of typhoid, 59
Monocyte
activity against *Candida*, 999
isolation of HIV-1 from, 706
Mononucleosis, role of γδ lymphocytes, 1013
Mycobacteria, infection, immunogenetics, 634
Mycobacterium avium-intracellulare
treatment with liposome-encapsulated aminoglycosides, in mice, 1262
bacteremia in AIDS, treatment for, 801
Mycobacterium chelonae, systemic infection in hemodialysis patients, 85
Mycobacterium tuberculosis, detection by PCR, 977
Mycoplasma pneumoniae, common antigen as heat-shock protein, 1039
Mycoplasma pulmonis, infection, enhanced NK cell function in, 1269

Nanophyetus salmincola, transmission by handling infected fish, 146
Neisseria meningitidis
lipid-modified azurin, localization and immune response, 336
prophylaxis, in complement deficiency, 932
Neisseria gonorrhoeae
acquisitional behavior, 938
lipid-modified azurin, localization and immune response, 336
maternal infection, risk for low birth weight, 531
Neopterin, and IFN-α, in measles, 449
Nephropathia epidemica, renal function, 716
Nephrotoxicity, due to aminoglycosides, relation to endotoxin, 721
Neurobrucellosis, increased adenosine deaminase activity, in CSF, 156
Neutropenia, in febrile patients, 381
Neutrophil
endotoxin-activated serum as priming agent, 242
priming, role of FMLP and C5a receptors, 242
respiratory burst oxidase, in humans, 1140
NIAID, and WHO report, respiratory syncytial and parainfluenza viruses, 402
Norwalk virus, host immunity, multiple-challenge study, 18
Nosocomial infection
diarrhea, risk for urinary tract infection, 948
due to *S. epidermidis*, 493

Onchocerciasis, IgG4 subclass antibody serology, 549
Opportunistic infection, in HIV infection, management, 858
Osteitis, hematogenous, due to *Y. enterocolitica*, 590
Osteomyelitis
isolation of *S. epidermidis* binding bone sialoprotein, 814
S. aureus, treatment with ampicillin/sulbactam, 52
V. vulnificus, 363
Otitis, malignant external, treatment with ciprofloxacin, 537
Otitis media, recurrent acute, prophylaxis, 806, 807
Outer membrane proteins, lipid-modified azurin, pathogenic *Neisseria*, 336
Oxacillin, time-kill studies with *S. aureus*, 1036

Papillomaviruses, human, detection by PCR, 113
Parainfluenza virus, pediatric infection, epidemiology, 640
Parvovirus
B19, numbness and tingling of fingers, 354
human, 603
Pediococcus acidilactici, bacteremia, 956
Penicillin
and iv immunoglobulin, effect on group B streptococci, 1225
prophylaxis against *N. meningitidis*, in complement deficiency, 932
tolerance in *A. haemolyticum*, 261
Peptic ulcer disease, due to *H. pylori*, 626
Perspective
immunization for group B streptococci, 917
neutrophil respiratory burst oxidase, 1140
pertussis and its prevention, 473
Pertussis
and HIV infection, 1296
and prevention, 473
antibody, in neonate, 487
serologic diagnosis, by ELISA, 966
symptoms and antibody response, 480
vaccines, 473, 480, 487
Phagocyte, IgA-mediated uptake of group B streptococci, effect of fibronectin, 236
Pili, *H. influenzae* type b, adherence to human mucosa, 274
Plasmids, of β-lactamase-producing enterococci and staphylococci, 54
Plasmodium falciparum, infection
immune response, 1025
mortality after poor response to quinine, 577
splenic Fc receptor function in, 555
treatment with quinine, consecutive-infusion regimen, 1305
Pneumocystis carinii
antibody response, in health and disease, 296
pneumonia, treatment with trimetrexate-leucovorin, in AIDS, 91
Pneumonia, due to
C. pneumoniae, 618
S. pneumoniae
naturally acquired antibody, 736
vaccine, efficacy, 728
P. carinii, treatment with trimetrexate-leucovorin, in AIDS, 91
Pneumonia, viral, in Filipino children, 175
Polymerase chain reaction
and antibody test, in HIV detection, 436
to detect
CMV DNA, in mice, 220
enterovirus, 787
HIV-1 proviral sequences, 1068
HPV in cervicovaginal cells, 113
M. tuberculosis, 977
R. prowazekii, 791
Shigella, 1252

Polyomavirus, JC, urinary excretion, in older patients, 1128
Polysaccharide
  group B streptococci, correlation with buoyant density, 741
  sulfated, anti-HIV activity in vitro, 208
Porphyria cutanea tarda, relation to HIV infection, 1032
Prostatitis, *H. fabianii*, 1040
Proteus mirabilis, adherence, in urinary tract infection, 525
Pseudomonas aeruginosa
  adherence, to respiratory epithelium, 541
  anti-TNFα monoclonal antibody in infection, 1148

Q fever, mode of transmission, 368
Quinine, for falciparum malaria, consecutive-infusion regimen, 1305

Renalin, incomplete killing of *M. chelonae* in dialysis, 85
Respiratory syncytial virus
  epidemiology, subtypes, 781
  pediatric infection, epidemiology, 640
Respiratory tract infection, due to
  C. pneumoniae, 618
  RSV, 640
  RSV, epidemiology, 781
Rheumatic fever, relation to Fc receptors, group A streptococci, 747
Rhinovirus, colds, kinin generation in nasal secretions, 120
Rickettsia prowazekii, detection by PCR, 791
Rimantidine, effect on cytotoxic T lymphocyte responses, in influenza A virus infections, 180
Rotavirus
  antibody levels, 352, 353
  antibody protection after rechallenge, in humans, 440
  gastroenteritis, immune protection of infants, 1099
  group A, serologic response, in pediatric infection, 1105
  immune response, in symptomatic and asymptomatic infection, 330
  SA11, inhibition by acetylated sialic acid, 116
  vaccine, live attenuated, antibody response in adults and infants, 667

Salmonella havana, decreased resistance to infection by prior antimicrobial exposure, 255
Salmonella typhi, monoclonal antibodies to flagellin, for diagnosis of typhoid, 59
Scedosporium inflatum, clinical spectrum, 102
Schistosoma mansoni, blastogenesis and IL-2 expression in human infection, 1284
Scrapie
  induced pancreatic lesions and hypoglycemia-hyperinsulinemia, 462
  infectivity titers, compared by dose-response analysis, 783
  resistance of infectivity, 467
Sexually transmitted disease, due to *N. gonorrhoeae*
  acquisitional behavior, 938
  risk factor for low birth weight, 531
Shiga toxin
  and other cytotoxins, association with neurologic manifestations in shigellosis, 961
  and Shiga-like toxin II, detection by ELISA, 134
Shigella
  detection by PCR, 1252
  dysentery and mortality due to, in Bangladesh, 500
  trimethoprim resistance, 1242
Shigella flexneri, glomerulonephritis and dysentery, 366
Shigella sonnei, plasmid analysis, 797
Shigellosis, neurologic manifestations, association with Shiga toxin and other cytotoxins, 961
Sinusitis, *S. aureus*, association with toxic shock syndrome, 953
Small round virus, causative agent for pediatric diarrhea, 571
Smallpox, neutralizing antibody, persistence after vaccination, 446
Staphylococci
  adherence, to peritoneal mesothelial cells, 266
  coagulase-negative
    ciprofloxacin-resistant, 41
    emergence of ciprofloxacin resistance in immunocompromised patients, 41
Staphylococcus aureus
  adherence
    to catheters, 1177
    to peritoneal mesothelial cells, 266
  antibiotic effect, time-kill studies, 1036
  comparison of antibiotic activity against, 1023
  experimental osteomyelitis, treatment with ampicillin/sulbactam, 52
  methicillin-resistant
    and cephem-resistant, susceptibility to β-lactam antibiotics, 250
    binding of β-lactam antibiotics, 1170
    endocarditis due to, 812
  phagocytosis by human lung phagocytes, 138
  sinusitis, relation to toxic shock syndrome, 953
Staphylococcus epidermidis
  adherence to peritoneal mesothelial cells, 266
  isolation from osteomyelitis, 814
  nosocomial infection, after cardiac surgery, 493
  phase variation, antibiotic resistance, virulence, 1153
  slime, inhibition of vancomycin and teicoplanin, 37
Staphylococcus haemolyticus, resistance to vancomycin, 45
Staphylococcus saprophyticus
  cystitis, treatment with trimethoprim, 942
  phase variation, antibiotic resistance, virulence, 1153
Streptococcus pneumoniae
  naturally acquired antibody, protection, 736
  vaccine, efficacy, 728

Teicoplanin
  inhibition of action by *S. epidermidis* slime extract, 37
  time-kill studies with *S. aureus*, 1036
Thrombophlebitis, septic cortical, 1216
Toxic shock syndrome, associated with *S. aureus* sinusitis, in children, 953
Toxoplasma gondii, infection, in pregnant women, 769
Toxoplasmosis, in pregnant women, outbreak, 769
Trichomonas vaginalis, isolates from women with and without colpitis macularis, 307
Trichomoniasis, isolates of *T. vaginalis* from women with and without colpitis macularis, 307
Trimethoprim
  resistance, in *Shigella*, 1242
  single-dose treatment, for cystitis in women, 942
Trimetrexate-leucovorin, treatment for *P. carinii* pneumonia, in AIDS, 91
Tuberculosis
  diagnosis by PCR, 977
  nosocomial transmission, associated with a draining abscess, 286
Tumor necrosis factor
  and IL-1 in septic shock and endotoxin fever, 79
  in leprosy and leishmaniasis, 988
Tumor necrosis factor/cachectin, prognostic value, in septic shock, 982
Typhoid fever
  antimicrobial treatment, 159
  immunodiagnosis using monoclonal antibodies to *S. typhi* flagellin, 59
Typhus, acute, detection by PCR, 791

Urinary tract infection, due to
  C. trachomatis, diagnosis by detection of antigen in urine, 124
  E. coli, evidence for clonality of infection, 230

E. coli, uropathogenic, DNA homology in, 518
P. mirabilis, 525

Vaccination, against influenza, antibody response, 333
Vaccine
AIDS, ethical issues involving volunteers, 356
capsular polysaccharide-protein conjugate, 821
group B streptococci, 917
H. influenzae
conjugate, 574
type b, risk in immunocompromised children, 926
hepatitis A virus
and hepatitis B virus, simultaneous, 865
immunogenicity in primates, 586
herpes simplex virus type 2, efficacy, 653
influenza B virus
attenuation, immunogenicity, efficacy, 22
in adult volunteers, 869
Japanese encephalitis virus, efficacy, 878
L. donovani, purified protein, 1313
pertussis, 473, 480, 487
pneumococcal, efficacy, 728
rabies, recombinant human, 27
rotavirus, efficacy of serotype 1 reassortant of bovine rotavirus WC3, 1099
varicella, efficacy, in leukemic children and healthy adults, 661
Vaginitis, due to
C. albicans, role of aspartate proteinase, 1276
T. vaginalis, 307
Vancomycin
inhibition of action by *S. epidermidis* slime extract, 37
resistance
in *P. acidilactici*, 956
in *S. haemolyticus*, 45
time-kill studies with *S. aureus*, 1036
Varicella, vaccine, live attenuated, 661
Varicella zoster virus, severity and clinical findings, in children, 1095
Vasculitis, cutaneous necrotizing, role of O_2-derived free radicals, 1020
Vibrio, wound infection, septicemia, 364
Vibrio cholerae, antibody to pili, protection in infant mouse, 1231
Vibrio parahaemolyticus
adherence to human ureteral mucosa, 361
and *V. vulnificus*, dual infection, 364
Vibrio vulnificus
and *V. parahaemolyticus*, dual infection, 364
osteomyelitis, 363
Viridans streptococci, endocarditis, clindamycin inhibition of glycocalyx production, 1221
Virulence
E. coli, relation to aerobactin and hemolysin production, 794
S. epidermidis and *S. saprophyticus*, 1153
Virus
CMV, infection in organ transplant recipients, 454
hepatitis B
cellular immune response to core antigens, 420
in vitro immune reponse to surface antigens, 412
parainfluenza, 402
respiratory syncytial, 402

Wound infection
surgical, culture method for detecting infection, 972
due to *V. vulnificus* and *V. parahaemolyticus*, 364

Yellow fever virus, immunogenic properties of purified proteins, 1134
Yersinia enterocolitica, osteitis, 59

Zidovudine
decreased susceptibility of HIV isolates, 326
in murine LP-BM5 retrovirus-induced immunodeficiency model, 1006
synergism and inhibition of replication of HIV, 1059
transfer by human placenta, 203